Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine

Diagnostic Microbiology and Infectious Disease

Volumn 80, Issue 1, 2014, Pages 19-25

  Mendes, Rodrigo E ^a   Costello, Andrew J ^a   Jacobs, Michael R ^b   Biek, Donald ^c   Critchley, Ian A ^c   Jones, Ronald N ^a  

^a JMI LABORATORIES   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c Cerexa Inc   (United States)

Author keywords

Pneumococci; Serotype; Vaccine

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTAROLINE; CEFTRIAXONE; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; LEVOFLOXACIN; LINEZOLID; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; VANCOMYCIN; ANTIINFECTIVE AGENT; PREVENAR13;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; CONCENTRATION RESPONSE; GEOGRAPHIC DISTRIBUTION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCHOOL CHILD; SEROTYPE; STREPTOCOCCUS PNEUMONIAE; UNITED STATES; ADOLESCENT; ANTIBIOTIC RESISTANCE; CLASSIFICATION; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; IMMUNOLOGY; INFANT; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PNEUMOCOCCAL INFECTIONS; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; HUMANS; INFANT; INFANT, NEWBORN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROGROUP; STREPTOCOCCUS PNEUMONIAE; YOUNG ADULT;

EID: 84926204908     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.05.020     Document Type: Article

References (31)

1. Ampofo K., Pavia A.T., Chris S., Hersh A.L., Bender J.M., Blaschke A.J., et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. Pediatr Infect Dis J 2012, 31:228-234.
2. Angoulvant F., Levy C., Grimprel E., Varon E., Lorrot M., Biscardi S., et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis 2014, 58:918-924.
3. Black S., Shinefield H., Baxter R., Austrian R., Bracken L., Hansen J., et al. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. Pediatr Infect Dis J 2004, 23:485-489.
4. Byington C.L., Samore M.H., Stoddard G.J., Barlow S., Daly J., Korgenski K., et al. Temporal trends of invasive disease due to Streptococcus pneumoniae among children in the intermountain west: emergence of nonvaccine serogroups. Clin Infect Dis 2005, 41:21-29.
5. Centers for Disease Control and Prevention (CDC) National, State, and Local area vaccination coverage among children aged 19-35 months - United States, 2006 August 31, 2007. CDC 2007, 56(34):880-885.
6. Centers for Disease Control and Prevention (CDC) Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine for adults with immunocompromising conditions: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep 2012, 61:816-819.
7. Clinical and Laboratory Standards Institute (CLSI) M07-A9. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard 2012, [Wayne, PA, USA]. 9th ed.
8. Clinical and Laboratory Standards Institute (CLSI) M100-S23. Performance standards for antimicrobial susceptibility testing: 23rd informational supplement 2013, [Wayne, PA, USA].
9. Dagan R., Givon-Lavi N., Zamir O., Fraser D. Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J 2003, 22:532-540.
10. European Committee on Antimicrobial Susceptibility Testing (EUCAST) Breakpoint tables for interpretation of MICs and zone diameters. Version 3.0 Available at, (January, Accessed January 1, 2013). http://www.eucast.org/clinical_breakpoints/.
11. Grijalva C.G., Nuorti J.P., Arbogast P.G., Martin S.W., Edwards K.M., Griffin M.R. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 2007, 369:1179-1186.
12. Hampton L.M., Farley M.M., Schaffner W., Thomas A., Reingold A., Harrison L.H., et al. Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines. J Infect Dis 2012, 205:401-411.
13. Hsieh Y.C., Lin T.L., Chang K.Y., Huang Y.C., Chen C.J., Lin T.Y., et al. Expansion and evolution of Streptococcus pneumoniae serotype 19A ST320 clone as compared to its ancestral clone, Taiwan 19F-14 (ST236). J Infect Dis 2013, 208:203-210.
14. Hsu K., Pelton S., Karumuri S., Heisey-Grove D., Klein J. Massachusetts Department of Public Health E. Population-based surveillance for childhood invasive pneumococcal disease in the era of conjugate vaccine. Pediatr Infect Dis J 2005, 24:17-23.
15. Hulten K.G., Kaplan S.L., Lamberth L.B., Barson W.J., Romero J.R., Lin P.L., et al. Changes in Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J Clin Microbiol 2013, 51:1294-1297.
16. Jacobs M.R., Good C.E., Bajaksouzian S., Windau A.R. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin Infect Dis 2008, 47:1388-1395.
17. Jacobs M.R., Good C.E., Windau A.R., Bajaksouzian S., Biek D., Critchley I.A., et al. Activity of ceftaroline against recent emerging serotypes of Streptococcus pneumoniae in the United States. Antimicrob Agents Chemother 2010, 54:2716-2719.
18. Jones R.N., Sader H.S., Moet G.J., Farrell D.J. Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009). Diagn Microbiol Infect Dis 2010, 68:334-336.
19. Kaplan S.L., Barson W.J., Lin P.L., Romero J.R., Bradley J.S., Tan T.Q., et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013, 32:203-207.
20. Leung M.H., Bryson K., Freystatter K., Pichon B., Edwards G., Charalambous B.M., et al. Sequetyping: serotyping Streptococcus pneumoniae by a single PCR sequencing strategy. J Clin Microbiol 2012, 50:2419-2427.
21. Link-Gelles R., Thomas A., Lynfield R., Petit S., Schaffner W., Harrison L., et al. Geographic and temporal trends in antimicrobial nonsusceptibility in Streptococcus pneumoniae in the post-vaccine era in the United States. J Infect Dis 2013, 208:1266-1273.
22. O'Brien K.L., Wolfson L.J., Watt J.P., Henkle E., Deloria-Knoll M., McCall N., et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5years: global estimates. Lancet 2009, 374:893-902.
23. Pai R., Gertz R.E., Beall B. Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol 2006, 44:124-131.
24. Pelton S.I., Huot H., Finkelstein J.A., Bishop C.J., Hsu K.K., Kellenberg J., et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr Infect Dis J 2007, 26:468-472.
25. Prere M.F., Fayet O.A. A specific polymerase chain reaction test for the identification of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2011, 70:45-53.
26. Richter S.S., Heilmann K.P., Dohrn C.L., Riahi F., Diekema D.J., Doern G.V. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis 2013, 19:1074-1083.
27. Rosen J.B., Thomas A.R., Lexau C.A., Reingold A., Hadler J.L., Harrison L.H., et al. Geographic variation in invasive pneumococcal disease following pneumococcal conjugate vaccine introduction in the United States. Clin Infect Dis 2011, 53:137-143.
28. Sharma D., Baughman W., Holst A., Thomas S., Jackson D., da Gloria Carvalho M., et al. Pneumococcal carriage and invasive disease in children before introduction of the 13-valent conjugate vaccine: comparison with the era before 7-valent conjugate vaccine. Pediatr Infect Dis J 2013, 32:e45-e53.
29. Song J.H., Dagan R., Klugman K.P., Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012, 30:2728-2737.
30. Tan T.Q. Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev 2012, 25:409-419.
31. Whitney C.G., Pilishvili T., Farley M.M., Schaffner W., Craig A.S., Lynfield R., et al. Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet 2006, 368:1495-1502.